Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6636227 | 0.99 | TACR1 (0.98) | TACR1GPBAR1 | |
| SCHEMBL6869637 | 0.91 | TACR1 (1.00) | TACR1GPBAR1 | |
| Hydrochloric Acid SCHEMBL6868501 | 0.90 | TACR1 (0.98) | TACR1GPBAR1 | |
| SCHEMBL1399482 | 0.88 | TACR1 (0.79) | TACR1GPBAR1 | |
| SCHEMBL6862826 | 0.87 | TACR1 (0.77) | TACR1GPBAR1 | |
| Hydrochloric Acid SCHEMBL6640269 | 0.87 | TACR1 (0.77) | TACR1GPBAR1 | |
| SCHEMBL12097864 | 0.86 | GPBAR1 (1.00) | GPBAR1 | |
| SCHEMBL5781472 | 0.84 | TACR1 (0.72) | TACR1GPBAR1 | |
| SCHEMBL6634454 | 0.84 | TACR1 (0.72) | TACR1GPBAR1 | |
| SCHEMBL5758941 | 0.83 | GPBAR1 (0.76) | TACR1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1984891-B | Process for the preparation of carboxamide pyridine derivatives useful as intermediates in the synthesis of NK-1 receptor antagonists | HOFFMANN LA ROCHE | 2012-08-08 | — | — | CN | claimed |
| EP-1776342-B1 | PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | claimed |
| US-7384939-B2 | Process for preparation of pyridine derivatives of NK-1 receptor antagonist | ROCHE COLORADO CORPORATION (US) | 2008-06-10 | — | — | US | claimed |
| EP-1656351-B1 | PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | claimed |
| CN-1984891-A | Process for the preparation of carboxamide pyridine derivatives useful as intermediates in the synthesis of NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2007-06-20 | — | — | CN | claimed |
| EP-1385577-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | claimed |
| US-20060014959-A1 | Process for preparation of pyridine derivatives of NK-1 receptor antagonist | ROCHE COLORADO CORPORATION (US) | 2006-01-19 | — | — | US | claimed |
| EP-1035115-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2004-09-29 | — | — | EP | claimed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | claimed |
| CN-1984891-B | Process for the preparation of carboxamide pyridine derivatives useful as intermediates in the synthesis of NK-1 receptor antagonists | HOFFMANN LA ROCHE | 2012-08-08 | — | — | CN | disclosed |
| EP-1776342-B1 | PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7384939-B2 | Process for preparation of pyridine derivatives of NK-1 receptor antagonist | ROCHE COLORADO CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| CN-1984891-A | Process for the preparation of carboxamide pyridine derivatives useful as intermediates in the synthesis of NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2007-06-20 | — | — | CN | disclosed |
| EP-1776342-A1 | PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060014959-A1 | Process for preparation of pyridine derivatives of NK-1 receptor antagonist | ROCHE COLORADO CORPORATION (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2006002860-A1 | PROCESS FOR PREPARING CARBOXAMIDE PYRIDINE DERIVATIVES USED AS INTERMEDIATES IN THE SYNTHESIS OF NK-1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-12 | — | — | WO | disclosed |
| EP-1035115-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2004-09-29 | — | — | EP | disclosed |
| EP-1394150-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014959-A1 | Process for preparation of pyridine derivatives of NK-1 receptor antagonist | BDKRB1, TACR1, NPSR1 | TACR1 2/4885GPBAR1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.